Combination therapy for treating muscular dystrophy patent
Summary
The European Patent Office granted Solidus Biosciences Patent EP3893940A1 covering combination therapies for treating muscular dystrophy, including genetic, protein-based, and viral vector approaches. The patent, classified under IPC codes A61K 48/00 and C12N 15/113, designates all EU member states plus Switzerland, Norway, and Turkey. This patent grant establishes intellectual property rights that may affect freedom-to-operate for competing therapeutic development programs.
What changed
The European Patent Office published Patent EP3893940A1 granting Solidus Biosciences intellectual property protection for combination therapies targeting muscular dystrophy. The patent covers gene therapy vectors (C12N 15/864), antisense oligonucleotides (C12N 15/113), and protein-based therapeutic combinations (C07K 14/47), with designated states spanning all EU member states plus Switzerland, Turkey, Norway, and other European jurisdictions.
Pharmaceutical and biotechnology companies developing competing muscular dystrophy therapies should evaluate freedom-to-operate implications. Any parties seeking to develop, manufacture, or commercialize similar combination approaches in designated territories may require licensing or design-around strategies. IP professionals should monitor for related continuation applications and potential international filing extensions.
What to do next
- Review patent claims for overlap with existing or planned programs
- Assess freedom-to-operate implications for competing therapeutic developments
- Monitor for related patent applications in the combination therapy space
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION THERAPY FOR TREATING MUSCULAR DYSTROPHY
Publication EP3893940A1 Kind: A1 Apr 01, 2026
Applicants
Solidus Biosciences, Inc.
Inventors
RAMU, Senthil, SCHNEIDER, Joel, MORGAN, Kathy, Ye, TSENG, Wen, Allen, OZSOLAK, Fatih, SOUSTEK-KRAMER, Meghan, REYES, Eric, MANDAVA, Sarath
IPC Classifications
A61K 48/00 20060101AFI20220819BHEP C12N 15/113 20100101ALI20220819BHEP C12N 15/63 20060101ALI20220819BHEP C12N 15/864 20060101ALI20220819BHEP C07K 14/47 20060101ALI20220819BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.